For: | Baran B, Akyüz F. Non-alcoholic fatty liver disease: What has changed in the treatment since the beginning? World J Gastroenterol 2014; 20(39): 14219-14229 [PMID: 25339808 DOI: 10.3748/wjg.v20.i39.14219] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v20/i39/14219.htm |
Number | Citing Articles |
1 |
Simone Coghetto Acedo, Cintia Rabelo e Paiva Caria, Érica Martins Ferreira Gotardo, José Aires Pereira, José Pedrazzoli, Marcelo Lima Ribeiro, Alessandra Gambero. Role of pentoxifylline in non-alcoholic fatty liver disease in high-fat diet-induced obesity in mice. World Journal of Hepatology 2015; 7(24): 2551-2558 doi: 10.4254/wjh.v7.i24.2551
|
2 |
Saira Nawaz, Rajkumar Chinnadurai, Saif Al‐Chalabi, Philip Evans, Philip A. Kalra, Akheel A. Syed, Smeeta Sinha. Obesity and chronic kidney disease: A current review. Obesity Science & Practice 2023; 9(2): 61 doi: 10.1002/osp4.629
|
3 |
Vyacheslav Buko, Ilya Zavodnik, Bartlomiej Palecz, Artur Stepniak, Siarhei Kirko, Alexej Shlyahtun, Wiesława Misiuk, Elena Belonovskaya, Oxana Lukivskaya, Elena Naruta, Irina Kuzmitskaya, Tatsiana Ilyich, Bayarmaa Erdenebayar, Sluken Rakhmadieva. Betulin/2-hydroxypropyl-β-cyclodextrin inclusion complex: Physicochemical characterization and hepatoprotective activity. Journal of Molecular Liquids 2020; 309: 113118 doi: 10.1016/j.molliq.2020.113118
|
4 |
Luciana M. A. Borém, João F. R. Neto, Igor V. Brandi, Deborah F Lelis, Sergio H. S. Santos. The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertension Research 2018; 41(6): 394 doi: 10.1038/s41440-018-0040-6
|
5 |
Daniel Silva Moraes, Deborah de Farias Lelis, João Marcus Oliveira Andrade, Lara Meyer, André Luiz Sena Guimarães, Alfredo Maurício Batista De Paula, Lucyana Conceição Farias, Sérgio Henrique Sousa Santos. Enalapril improves obesity associated liver injury ameliorating systemic metabolic markers by modulating Angiotensin Converting Enzymes ACE/ACE2 expression in high-fat feed mice. Prostaglandins & Other Lipid Mediators 2021; 152: 106501 doi: 10.1016/j.prostaglandins.2020.106501
|
6 |
Everton Cazzo, Martinho Antonio Gestic, Murillo Pimentel Utrini, Felipe David Mendonça Chaim, Francisco Callejas-Neto, José Carlos Pareja, Elinton Adami Chaim. Bariatric surgery in individuals with liver cirrhosis: A narrative review. Revista da Associação Médica Brasileira 2017; 63(2): 190 doi: 10.1590/1806-9282.63.02.190
|
7 |
Alessandra Ferramosca, Mariangela Di Giacomo, Vincenzo Zara. Antioxidant dietary approach in treatment of fatty liver: New insights and updates. World Journal of Gastroenterology 2017; 23(23): 4146-4157 doi: 10.3748/wjg.v23.i23.4146
|
8 |
Qianqian Zheng, Masaya Kawaguchi, Hayato Mikami, Pan Diao, Xuguang Zhang, Zhe Zhang, Takero Nakajima, Takanobu Iwadare, Takefumi Kimura, Jun Nakayama, Naoki Tanaka. Establishment of Novel Mouse Model of Dietary NASH Rapidly Progressing into Liver Cirrhosis and Tumors. Cancers 2023; 15(14): 3744 doi: 10.3390/cancers15143744
|
9 |
Yu-Tao Zhan, Hai-Ying Su, Wei An. Glycosyltransferases and non-alcoholic fatty liver disease. World Journal of Gastroenterology 2016; 22(8): 2483-2493 doi: 10.3748/wjg.v22.i8.2483
|
10 |
Emanuela Esposito, Michela Campolo, Marika Cordaro, Giovanna Casili, Salvatore Cuzzocrea. Autophagy Networks in Inflammation. 2016; : 365 doi: 10.1007/978-3-319-30079-5_17
|
11 |
Mikhaïl Van Herck, Luisa Vonghia, Sven Francque. Animal Models of Nonalcoholic Fatty Liver Disease—A Starter’s Guide. Nutrients 2017; 9(10): 1072 doi: 10.3390/nu9101072
|
12 |
L. Farzin, S. Asghari, M. Rafraf, M. Asghari-Jafarabadi, M. Shirmohammadi. No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease. International Journal for Vitamin and Nutrition Research 2020; 90(3-4): 279 doi: 10.1024/0300-9831/a000528
|
13 |
Dahae Lee, Tuy An Trinh, Myoung-Sook Shin, Ki Sung Kang. Recent Advancements in Microbial Diversity. 2022; : 209 doi: 10.1016/B978-0-12-822368-0.00009-8
|
14 |
Nicholas W.S. Chew, Bryan Chong, Cheng Han Ng, Gwyneth Kong, Yip Han Chin, Wang Xiao, Mick Lee, Yock Young Dan, Mark D. Muthiah, Roger Foo. The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases. Frontiers in Genetics 2022; 13 doi: 10.3389/fgene.2022.971484
|
15 |
Pegah Golabi, Cameron T Locklear, Patrick Austin, Sophie Afdhal, Melinda Byrns, Lynn Gerber, Zobair M Younossi. Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review. World Journal of Gastroenterology 2016; 22(27): 6318-6327 doi: 10.3748/wjg.v22.i27.6318
|
16 |
И.Р. Агабабян, Ш.Ш. Садыкова. Pleyotropic Effects of Statins Non-Alcoholic Fat Disease of the Liver Non-Alcoholic Steatohepatitis. Рецепт 2022; (2): 194 doi: 10.34883/PI.2022.25.2.006
|
17 |
Mikhaïl A. Van Herck, Jonas Weyler, Wilhelmus J. Kwanten, Eveline L. Dirinck, Benedicte Y. De Winter, Sven M. Francque, Luisa Vonghia. The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Frontiers in Immunology 2019; 10 doi: 10.3389/fimmu.2019.00082
|
18 |
Samir Pathak, Sanjay Pandanaboyana, Ian Daniels, Neil Smart, K.R. Prasad. Obesity and colorectal liver metastases: Mechanisms and management. Surgical Oncology 2016; 25(3): 246 doi: 10.1016/j.suronc.2016.05.021
|
19 |
Niki Katsiki, Dimitrios Tousoulis. Diabetes mellitus and comorbidities: A bad romance. Hellenic Journal of Cardiology 2020; 61(1): 23 doi: 10.1016/j.hjc.2020.02.009
|
20 |
Nicholas Siebers, Melissa Palmer, Debra G. Silberg, Lee Jennings, Caleb Bliss, Patrick T. Martin. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. European Journal of Drug Metabolism and Pharmacokinetics 2018; 43(1): 91 doi: 10.1007/s13318-017-0429-7
|
21 |
Seoung-Woo Lee, Su-Min Baek, Kyung-Ku Kang, A-Rang Lee, Tae-Un Kim, Seong-Kyoon Choi, Yoon-Seok Roh, Il-Hwa Hong, Sang-Joon Park, Tae-Hwan Kim, Kyu-Shik Jeong, Jin-Kyu Park. Vitamin C Deficiency Inhibits Nonalcoholic Fatty Liver Disease Progression through Impaired de Novo Lipogenesis. The American Journal of Pathology 2021; 191(9): 1550 doi: 10.1016/j.ajpath.2021.05.020
|
22 |
Vasilios G Athyros. Statins for the Treatment of Non Alcoholic Fatty Liver Disease in Patients with Metabolic Syndrome. Journal of Diabetes, Metabolic Disorders & Control 2016; 3(1) doi: 10.15406/jdmdc.2016.03.00057
|
23 |
Vasilios G Athyros, Konstantinos Tziomalos, Niki Katsiki, Michael Doumas, Asterios Karagiannis, Dimitri P Mikhailidis. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology 2015; 21(22): 6820-6834 doi: 10.3748/wjg.v21.i22.6820
|
24 |
Björn Carlsson, Daniel Lindén, Gabriella Brolén, Mathias Liljeblad, Mikael Bjursell, Stefano Romeo, Rohit Loomba. Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics 2020; 51(12): 1305 doi: 10.1111/apt.15738
|
25 |
Masoumeh Akhlaghi. Non-alcoholic Fatty Liver Disease: Beneficial Effects of Flavonoids. Phytotherapy Research 2016; 30(10): 1559 doi: 10.1002/ptr.5667
|
26 |
Tian Shen, Bilin Xu, Tao Lei, Lin Chen, Cuiping Zhang, Zhenhua Ni. Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway. Experimental and Therapeutic Medicine 2018; doi: 10.3892/etm.2018.6554
|
27 |
Farah Ahsan, Federico Oliveri, Harshit K Goud, Zainab Mehkari, Lubna Mohammed, Moiz Javed, Aldanah Althwanay, Ian H Rutkofsky. Pleiotropic Effects of Statins in the Light of Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Cureus 2020; doi: 10.7759/cureus.10446
|
28 |
Wan-jun Zhao, Yang-ping Bian, Qiu-hui Wang, Fei Yin, Li Yin, Yong-lan Zhang, Jian-hui Liu. Blueberry-derived exosomes-like nanoparticles ameliorate nonalcoholic fatty liver disease by attenuating mitochondrial oxidative stress. Acta Pharmacologica Sinica 2022; 43(3): 645 doi: 10.1038/s41401-021-00681-w
|
29 |
Konstantinos Kargiotis, Vasilios G Athyros, Olga Giouleme, Niki Katsiki, Evangelia Katsiki, Panagiotis Anagnostis, Chrysoula Boutari, Michael Doumas, Asterios Karagiannis, Dimitri P Mikhailidis. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World Journal of Gastroenterology 2015; 21(25): 7860-7868 doi: 10.3748/wjg.v21.i25.7860
|
30 |
Marcio H. Miname, Raul D. Santos. Fatty liver, inflamed blood and calcified coronary arteries: Lessons and uncertainties from the multiethnic study of atherosclerosis -commentary on the study of Al Rifai et al.. Atherosclerosis 2015; 239(2): 634 doi: 10.1016/j.atherosclerosis.2015.02.041
|
31 |
Seyed Moayed Alavian, Hosein Zadi. The Relation Between Non-alcoholic Fatty Liver Disease and the Risk of Coronary Heart Disease. Multidisciplinary Cardiovascular Annals 2022; 13(1) doi: 10.5812/mca-121262
|